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ABSTRACT 
Background: Limited successes of gene finding for Major Depressive Disorder (MDD) may be 
partly due to phenotypic heterogeneity. We tested whether the genetic load for MDD, bipolar 
disorder (BIP), and schizophrenia (SCZ) is increased in phenotypically more homogenous MDD 
patients identified by specific clinical characteristics.  
Methods: Patients (n=1539) with a DSM-IV MDD diagnosis and controls (n=1792) were from two 
large (NESDA and NTR) cohort studies. Genomic profile risk scores (GPRS) for MDD, BIP and SCZ 
were based on meta-analyses results of the Psychiatric Genomics Consortium. Regression 
analyses (adjusted for year of birth, gender, three principal components) examined the 
association between GPRS with characteristics and with MDD subgroups stratified according to 
the most relevant characteristics. The proportion of liability variance explained by GPRS for each 
MDD subgroup was estimated. 
Result: GPRS-MDD explained 1.0% (p=4.19e
-09
) of MDD variance, and 1.5% (p=4.23e
-09
) for MDD 
endorsing 9 DSM symptoms. GPRS-BIP explained 0.6% (p=2.97e
-05
) of MDD variance and 1.1% 
(p=1.30e
-05
) for MDD with age at onset <18 years. GPRS-SCZ explained 2.0% (p=6.15e
-16
) of MDD 
variance, 2.6% (p=2.88e
-10
) for MDD with higher symptom severity, and 2.3% (p=2.26e
-13
) for 
MDD endorsing 9 DSM symptoms. An independent sample replicated the same pattern of 
stronger associations between cases with more DSM symptoms, as compared to overall MDD, 
and GPRS-SCZ.   
Conclusion: MDD patients with early age at onset and higher symptom severity have an 
increased genetic risk for three major psychiatric disorders, suggesting that it is useful to create 
phenotypically more homogenous groups when searching for genes associated with MDD.   
     
 
INTRODUCTION 
Major depressive disorder (MDD) has long been recognized to be heritable (~37%,(1)). However, 
today, the largest genome-wide association study (GWAS) in MDD by the Psychiatric Genomics 
Consortium (PGC) has failed to find significant associations with single genetic variants (SNPs).(2) 
One likely reason why it failed is that current available sample sizes are underpowered to detect 
small genetic effects;(3) studies have shown that a large proportion of MDD liability is due to 
joint polygenic effect of common SNPs with small effects scattered across the genome and 
shared with other psychiatric disorders such as bipolar disorder (BIP) and schizophrenia 
(SCZ).(3;4) A second reason may be MDD’s clinical heterogeneity: various patients with the same 
diagnosis will have experienced a differential illness course with variation in e.g. experienced 
number-, duration-, and severity of episodes.(5) It has therefore been suggested that GWAS 
studies should be done in phenotypically more homogenous MDD patients.(2;3) The Converge 
Consortium showed this by examining recurrent MDD cases in Chinese women.(6) However, 
there might be other characteristics that could be selected to enhance the genetic signal. Based 
on family studies(7;8) it has been suggested that the highest genetic load will be found in the 
most severe MDD phenotype, e.g. patients with young age at onset, longer (chronic) duration-, 
higher severity of symptoms, and recurrent episodes.(1;9;10) Moreover, clinical staging 
strategies using jointly different clinical characteristics to define stages of MDD progression(11–
13) may also be applied.  
  To our knowledge it has been barely examined whether genome-wide genomic profile 
risk scores (GPRS) are associated with clinical depression characteristics that indicate a more 
severe MDD phenotype. One study in depression suggests that a higher GPRS increases an 
individual’s susceptibility for experiencing chronically high levels of depressive symptoms.(14)  
   
     
 
  The current study will examine whether the genetic risk for MDD, BIP and SCZ estimated 
using GPRS generated from PGC meta-analysis results(2;15;16), is increased in phenotypically 
more homogenous MDD subgroups of patients stratified by clinical characteristics reflecting a 
more severe MDD phenotype (younger age at onset, longer duration of depressive symptoms, 
positive MDD family history, more DSM symptoms, higher severity of depressive symptoms, and 
the presence of recurring MDD episodes). In addition to single characteristics, we additionally 
stratify patients according to an established MDD clinical staging model reflecting MDD 
progression.(12;13) Finally, we aim to replicate main findings in an independent dataset.(17)  
 
MATERIALS & METHODS 
Sample 
The sample consisted of 3331 unrelated participants (median year of birth 1967, range 1926-
1994) of North-European ancestry from the Netherlands Study of Depression and Anxiety 
(NESDA) (n=1851) and from the Netherlands Twin Register (NTR) (n=1480). The methodology of 
both NESDA and NTR and their biobank projects have been extensively described 
elsewhere.(18–20) The genetic sample selection is identical to the one used by Milaneschi et 
al.(21) 
  In short, NESDA is an ongoing longitudinal study into the onset and course of depressive 
and anxiety disorders. At baseline (2004-2006) 2981 adults between the age of 18 and 65 were 
recruited from community (19%), general practice (54%) and specialized mental health care 
(27%) to represent the entire developmental spectrum of both disorders, including healthy 
controls. After baseline, 2, 4 and 6-year follow-up assessments have been performed.   
  NTR has collected longitudinal data on Dutch twin families involving nearly 40,000 adult 
     
 
participants. The ethical review boards of contributing universities approved both studies and all 
participants signed informed consent.  
 
MDD diagnoses. 
The present study consisted of 1539 cases with a lifetime diagnoses of MDD (history of an MDD 
episode during any of their interviews) and 1792 controls. All cases were drawn from NESDA. 
The presence of MDD was assessed with the DSM-IV Composite International Diagnostic 
Interview (CIDI) version 2.1.(22) administered by specially trained research staff at baseline or 
one of the biannual follow-up assessments. From NESDA, we selected healthy controls (n=312), 
participants without lifetime MDD or anxiety disorder.  
  From NTR, the majority of controls (n=1480) were drawn, participants who had no 
report of MDD, a low factor score based on a multivariate analyses of depressive complaints, 
anxiety, neuroticism and somatic anxiety.(23;24) 
 
Clinical characteristics. 
For MDD cases (all from NESDA) several clinical characteristics were assessed. Age at onset was 
ascertained via CIDI interview. Duration of depressive symptoms was examined with the Life-
Chart,(25) and expressed as the percentage of ~10 years (~4 years before baseline +  ~6 years of 
follow-up) spent with depressive symptoms. Presence of a first-degree family (no/yes) member 
with depression was assessed with the family-tree method.(26) Two different measures indexed 
depression severity: the highest number of DSM symptoms ever endorsed during an MDD 
episode extracted from the CIDI (range 5-9), and the average score on 4 measures (at each 
assessment) of the inventory of depressive symptom (IDS).(27) Recurring MDD episodes 
(yes/no) was extracted from the CIDI. Finally, we applied a clinical staging algorithm(12;13;28) 
     
 
(supplement-page 6, eFigure1), combining different clinical characteristics. Cases were assigned 
to three stages: stage 2 (n=303) first episode; stage 3 (n=631) recurrent/relapse episode; stage 4 
(n=605) chronic, an episode lasting longer than 2 years as indicated by the CIDI at baseline, or 
the life-chart during follow-up.  
 
Genotyping and genetic relationship matrix 
Blood sample collection and DNA extraction methods have been previously described.(18) 
Autosomal SNPs were genotyped on the Affymetrix 6.0 Human Genome-Wide SNP Array in 
three separate batches. Quality control (QC) steps have been previously described.(29;30) 
Primary analyses included 497.347 SNPS. Additional stringent QC was performed to build a 
genetic-relationship-matrix (GRM) to reduce the possibility that estimates from GRM-based 
analyses could be inflated by artifacts. The remaining 435,579 SNPs were used to build the GRM 
using GCTAv.1.24.1(31) Supplement-page 3 describes QC steps. 
 
Genomic profile risk scores (GPRS) 
As previously described(21) (more detail in supplement-page 3), results from the PGC were used 
to derive GPRS for MDD(2), BIP(15), and SCZ(16). Eight sets of scores alleles were selected based 
on significance thresholds (Pt <.0001, <.001, <.005, <.01, <.05, <.1, <.5, <1) of the discovery 
samples associations. GPRS were calculated as the number of scores alleles weighted by effect 
sizes (log-OR) from the discovery statistics (number of SNPs included for each Pt see 
supplement-eTable 2). GPRS construction method based on LD pruning and P-thresholding may 
limit their predicting accuracy by discarding information on LD structure.(32) Additionally, we 
derived GPRS using the LDpred approach using LD information from a reference panel.(32) Both 
     
 
GPRS thresholds and LDpred were standardized to a mean of zero and standard deviation of one 
to aid interpretation of results. 
 
Statistical analyses 
Differences in demographics between MDD cases and controls were examined using Mann-
Whitney u-tests for continuous and chi-square test for categorical variables.  
  Firstly, focusing on MDD cases (n=1539) we regressed genetic risk (GPRS-thresholds and 
LDpred) over clinical characteristics of MDD (age at onset, duration of symptoms, family history, 
number of DSM symptoms, severity of symptoms, recurring episodes, stages) using linear 
regression analyses. In order to discard spurious correlations we applied a strategy combining 
permutation-based empirical p-values GPRS of the same characteristics and false discovery rate 
across main clinical characteristics for each GPRS (see supplement-page 4). Only the GPRS-
characteristic pairs showing the most consistent (higher number of significant tests across GPRS) 
profile of associations were selected for further analyses. 
 Thus, MDD cases were stratified in subgroups of similar dimensions (based on 
distribution quantiles for continuous characteristics) according to each clinical characteristic 
selected in the previous step. The associations between GPRS and MDD (subgroups) were 
estimated with (multivariate) logistic regressions with controls as reference.   
  Next, the proportion of variance explained by GPRS on the liability scale for MDD 
(subgroups) was estimated using the R2 coefficient proposed by Lee et al.,(33) which is directly 
comparable with heritability and robust against ascertainment bias. Linear transformation on 
the liability scale was based on prevalence (K) of 0.18 for MDD (Dutch lifetime prevalence;(34) 
Ks for subgroups were empirically derived by dividing the prevalence for MDD by the number of 
subgroups.  
     
 
  Finally, the total variance in liability explained by the joint effect of all SNPs (SNP-
heritability, h
2 
SNP) for specific subsets of MDD selected according to clinical characteristics was 
estimated using genomic-relationship-matrix restricted maximum likelihood (GREML) 
analyses.(35) The h
2 
SNP is estimated in a linear mixed model in which the measure of genetic 
similarity (based on the GRM) is included as a random effect to predict the phenotype.  
Furthermore, the genetic covariance (COV) between specific subsets of MDD selected according 
to clinical characteristics and the traits on which the risk scores were trained was estimated 
using the AVENGEME package(36) utilizing the results from GPRS analyses (applied settings in 
supplement-eTable 4).  
 All analyses were adjusted for year of birth, gender, and three ancestry informative 
principal components to take possible population stratification into account.(30) Analyses, were 
performed with SPSS (v. 20.0, IBMcorp, 2011), R (v. 3.2.3, R Project for Statistical Computing) 
and GCTAv.1.24.1.(31) Nominal significance was set at p<0.05, using two-tailed tests. 
 
Replication sample 
One main finding was replicated in RADIANT-UK an independent cohort(37), from which we 
selected 1602 cases with a lifetime MDD diagnosis and 1390 controls who screened for absence 
of any psychiatric disorder. MDD presence was assessed with the schedules for clinical 
assessment in neuropsychiatry (SCAN) interview.(38)  
  Imputed (HapMap3) genotype data of RADIANT-UK were processed according to QC 
steps described in detail in a previous publication by our group.(39) GPRS-SCZ were prepared on 
76,201 independent SNPs (see supplement-page 5, eTable 6). 
  RADIANT-UK analyses were adjusted for age at interview, gender, and ten principal 
components.(17)  
     
 
 
RESULTS 
Cases (n=1539) were older, and more often female than controls (n=1792), see Table 1. Of 
cases, 70.5% had recurrent episodes. Chronic episodes (stage 4, lasting longer than two years), 
were experienced by 33% of those with a first and >40% of those with a recurrent episode.  
 
Clinical characteristics and GPRS  
Within the MDD cases (n=1539), the regression analyses showed consistent patterns of 
associations for five GPRS-characteristic relationships (supplement-eTable 1): high GPRS-MDD 
with increased number of DSM symptoms (4 significant, 3 of which with FDR q <0.10; top: 
Pt<.05, β .063, SE .026, empirical P-value=.014), high GPRS-BIP with earlier age at onset (5 
significant, 3 of which with FDR q <0.10; top: Pt<.005, β -.115, SE .031, empirical P-value=2e
-04
), 
and high GPRS-SCZ with higher IDS scores (5 significant, 4 of which with FDR q <0.10;  top: 
Pt<.01, β .089, SE .025, empirical P-value=3.74e
-04
). Both high GPRS-BIP and high GPRS-SCZ were 
also associated with number of DSM symptoms (GPRS-BIP 3 significant, 1 of which with FDR q 
<0.10; top: Pt<0.05, β .065, SE .026, empirical P-value=.012; GPRS-SCZ 3 significant, 2 of which 
with FDR q <0.10; top: LDpred, β .064, SE .026, empirical P-value=.013). These five GPRS-
characteristic pairs were carried forward in subsequent analyses. 
  Family history, duration of symptoms, recurring episodes, and MDD stages showed no 
consistent associations with GRPS.  
 
Subgroup analyses   
 MDD cases were stratified in subgroups of approximately similar dimensions according to age at 
onset quartiles (Q1 >37 years (n=392), Q2 26-37 years (n=380), Q3 18-25 years (n=398), Q4 <18 
     
 
years (n=360)), number of DSM symptoms (DSM5/6 (n=244), DSM7 (n=302), DSM8 (n=442), 
DSM9 (n=499)) and IDS scores quartiles (IDS<13 (n=384), IDS 13-20.25 (n=385), >20.25-29 
(n=387), and IDS>29 (n=377)).  
 Figure 1 depicts the proportion of variance explained by GPRS on the liability scale for 
MDD (subgroups); p-values are from (multinomial) logistic regression (full results in supplement-
eTable 3). GPRS-MDD, explained maximal 1.0% of liability variance for overall MDD, and 1.5% for 
MDD endorsing 9 DSM symptoms. GPRS-BIP explained maximal 0.6% for overall MDD, 1.1% for 
MDD with age at onset <18 years, and 0.7% for MDD endorsing 9 DSM symptoms. GPRS-SCZ 
explained maximal 2.0% for overall MDD, 2.6% for MDD with IDS score >29, and 2.3% for MDD 
endorsing 9 DSM symptoms.  
  Analyses were repeated collapsing the 2 subgroups with the highest explained variance 
for each characteristic: GPRS-MDD explained maximal 1.1% of liability variance for MDD 
endorsing ≥8 DSM symptoms (DSM-high, n=941); GPRS-BIP maximal 0.8% for MDD with an 
onset <26 years (AaO-young, n=758), and maximal 0.9% for DSM-high; and GPRS-SCZ maximal 
2.7% for MDD with IDS scores >20.25 (IDS-high, n=764) and 2.2% for MDD DSM-high. 
 
Previous analyses were repeated after the inclusion of 590 controls selected with less stringent 
criteria (see supplement-page 5): results were unchanged suggesting that different selection 
criteria for controls do not impact on the association with GPRS. 
 
SNP-heritability of MDD subgroups and Genetic Covariance with psychiatric traits. 
We estimated h
2 
SNP for the subgroups of MDD AaO-young, DSM-high and IDS-high, allowing us 
to focus on approximately half of the cases. SNP-heritability could not be reliably estimated for 
AaO-young  (K=0.09; est=.208, se=0.15, p=7.95e
-2
). This may suggests that the drop in (half) 
     
 
sample size was not balanced by an increased genetic homogeneity of this subgroup. Indeed, 
considering the results depicted in Figure 1, an increased genetic signal may be expected 
especially at very early age at onset, which would not allow us to retain a substantial sample size 
for GREML analyses. GREML analyses showed that h
2
SNP estimates were 0.44 for DSM-high 
(K=0.12; se= 0.14, p=8.24e
-4
), and 0.48 for IDS-high (K=0.09; se=0.15, p= 5.52e
-4
), although all 
with large standard errors due to restricted sample sizes. Estimates for DSM-high and IDS-high 
were suggestively higher than the estimate for MDD-overall previously reported in same sample 
(estimate=0.31; se=0.13; p=0.006)(21), although with overlapping confidence boundaries. The 
genetic covariance with bipolar disorder was 0.16 (95%CI, 0.11-0.22) when focusing on cases 
with AaO-young. The genetic covariance with schizophrenia was 0.11 (95% CI 0.09-0.13) when 
focusing on cases with IDS-high, and 0.12 (95%CI, 0.10-0.14) in cases with DSM-high.  
 
Replication: GPRS-SCZ and MDD with high number of DSM symptoms. 
We used RADIANT-UK to replicate our finding on increased GPRS-SCZ in cases with a high 
number of DSM symptoms (DSM-high, endorsing 8-9 symptoms). We selected this association as 
benchmark for several reasons: (i) DSM symptoms were available in both cohorts (IDS only in 
NESDA) and had a similar distribution (see supplement-eFigure 4); (ii) GPRS-SCZ explained a 
higher proportion of liability variance for DSM-high than GPRS-MDD (Figure 1); (iii) RADIANT-UK 
had no overlapping samples with PGC-SCZ discovery(16), while shared samples with PGC-MDD 
and PGC-BIP discovery sets.(2;15) The association between GPRS-BIP and young MDD onset is 
replicated in an under review PGC paper based on all the contributing cohorts (including NESDA 
and RADIANT-UK) and therefore was not considered further here.  
  Polygenic scores analyses in NESDA predicting DSM-high (941 cases versus 1792 
controls) had ≥80% power (estimated using the AVENGEME package(36), parameter settings in 
     
 
supplement-eTable 5) to detect a significant (α=0.05) association for GPRS-SCZ with Pts 
equal/higher than <0.01, with an expected R
2
 range of 0.3-1.8%. In RADIANT-UK, the power to 
detect the same significant association with 878 cases and 1390 controls was ≥80% for GPRS-SCZ 
with Pts equal/higher than <0.05, with an expected R
2
 range of 0.8-1.4% (parameter settings in 
supplement-eTable 8).     
  RADIANT-UK cases (n=1602) were older (mean=46.4yrs) than controls (n=1390) 
(mean=41.8yrs), and more often female (70.6% vs. 60.2%). 1462 cases had information on the 
number of DSM symptoms (median 8.00 range 5-9) experienced. GPRS-SCZ, explained maximal 
0.9% of liability variance for overall MDD, and 1.1% for DSM-high (n=878) (Figure 2, supplement-
eTable 7). 
  Pooled data-analyses, of the odds ratios derived from logistic regression analyses 
comparing the GPRS-SCZ in MDD overall versus controls and in MDD DSM-high versus controls 
both in NESDA and RADIANT-UK, showed that the odds for DSM-high versus controls were 
higher than the odds for MDD overall versus (Figure 3, supplement-eTable 9). 
  
DISCUSSION 
The current study examined whether the genetic risk for MDD, bipolar, and schizophrenia is 
increased in phenotypically more homogenous MDD subgroups of patients stratified by clinical 
characteristics reflecting a more severe MDD phenotype and stratified by clinical MDD stages 
reflecting progression of MDD. The present findings showed that MDD cases with a younger age 
at onset have a higher genetic load for bipolar disorder, and those with severe depression, as 
indexed by repeated measure of depressive symptoms, had higher genetic risk for 
schizophrenia. Moreover, cases with a high number of endorsed DSM symptoms showed also 
higher genetic risk for all major psychiatric disorders considered.  
     
 
  Differential association between polygenic scores for different psychiatric disorders and 
MDD specific clinical characteristics indicate that these features may be able to identify specific 
subgroups of depressed patients genetically more similar to the discovery traits. Indeed, 
polygenic score for bipolar explained 0.6% of liability variance for MDD and 1.1% when focusing 
on cases with early age at onset. Similarly, polygenic score for schizophrenia explained 2.0% of 
liability variance for MDD and 2.7% when focusing on cases with high symptoms severity. 
Association of polygenic scores of a trait (e.g. GPRS-MDD) on subgroups of the same trait (e.g. 
MDD characteristic groups) is often more difficult to interpret, especially when the index 
characteristics and its distribution are unknown in the discovery data.(35) However, in this case 
some interpretation is more plausible, as the number of DSM symptoms, associated with 
polygenic score of MDD, may clearly represent a proxy for disease severity. A further noticeable 
finding is that GPRS-SCZ scores explained the highest proportion of variance in MDD liability, 
higher than GPRS-MDD scores. This higher explanatory power is attributable to the larger 
training set for GPRS-schizophrenia(40), in a previous paper we calculated that if we would have 
the same size of training set for depression GPRS-MDD as used for GPRS-SCZ, we would have at 
least similar variance explained.(21) 
  The hypothesis that phenotypical more homogenous MDD cases as stratified by 
characteristics reflecting a more severe MDD phenotype (young age at onset, recurrent, chronic) 
have an increased genetic load is among other things based on the finding that some 
characteristics predict a familial risk on major depression. The risk of depression has consistently 
shown to be higher in family members of probands with early-onset recurrent MDD than family 
members of late-onset single episode.(1; 7)Our finding that GPRS-BIP is significantly higher in a 
young onset versus later onset MDD could suggest that patients with an early onset of 
depression may have a higher genetic risk to develop bipolar disorder later in life. This is in line 
     
 
with literature showing that the age at onset for bipolar disorder is generally younger than the 
age at onset for MDD(7), and that an early age at depression onset is a risk factor for developing 
bipolar disorder later on.(41–43) One other study on MDD patients showed that early age at 
onset (<18 years) was associated with a higher genetic bipolar load.(44) Besides age at onset, we 
found that higher number of DSM symptoms and higher severity of depressive symptoms are 
also associated with an increased genetic risk, especially GPRS-SCZ. It could be that a higher 
genetic risk for schizophrenia might cause more severe MDD. It is known that severe forms of 
MDD often presents itself with psychotic symptoms.(45;46) To our knowledge one other study 
has examined the association between depression severity and genetic load, and found that the 
mean number of depressive symptoms was associated with genetic risk.(14) This study, 
however, only included older adults (>50yrs), GPRS were based on same trait examined, and no 
official depression diagnosis was made. In a larger sample than the current one, it would be 
interesting to examine whether this association between high number/severity of symptoms 
and increased genetic schizophrenic risk is driven by specific symptoms that are particularly 
relevant to psychosis.   
   We found no associations between genetic load and duration of symptoms, family 
history of depression, recurring MDD episodes, and MDD stage. An explanation for our negative 
results on family history and GPRS could be that family history is important for the onset of 
MDD, but in persons with MDD a higher genetic load exists regardless of their family history. In 
addition, our measurement of family history may not have been very sensitive to distinguish 
only the most severe family cases, as reported family history was quite high. Finally, familial 
aggregation may be considered a rather broad index for genetic risk (which may include also the 
effect of all kinds of genetic influences and the shared environment). In the current study we 
used GPRS, which rely only on the additive effect of common variants, while we considered only 
     
 
the additive genetic risk arising from common variants. A reason why we did not find a genetic 
load difference between first and recurrent episodes may be that those with a first episode will 
develop a recurrent episode in the future and therefore will be phenotypically the same as those 
that have already a recurrent episode. In addition, quite a large proportion of our first episode 
patients had already a chronic episode. Finally, there was no significant difference in genetic 
load across the staging model of MDD either (see supplement-page 6).  
  Overall, the present results suggest that subgroups of MDD patients selected according 
to specific clinical characteristics may be genetically more homogenous. For instance, estimates 
of the proportions of variance explained by common genetic variants on the liability for MDD 
cases with severe symptoms (48%) and high number of endorsed DSM symptoms (44%) were 
suggestively higher than the estimate obtained for overall MDD in the same sample (31%).(21) 
Nevertheless, these results require replication in larger samples, as the limited sample size 
determined substantial uncertainty around the estimates. These genetically more homogenous 
sub-phenotypes could be applied to large gene-discovery studies in order to boost the power to 
detect variants associated to MDD. However, detailed data on the clinical characteristics may 
not be available in all cohorts participating in large collaborative genetic studies. In this case a 
simpler strategy based on data likely available in the majority of studies may still represent a 
viable option to harmonize sub-phenotypes across cohorts. In the present study MDD with 
severe symptoms (as indexed by repeated measures of the Inventory of Depressive Symptoms) 
showed the highest SNP-heritability, and therefore may have represented the best potential 
candidate sub-phenotype. However, not all MDD genetic studies necessarily include longitudinal 
measurements by the same scale. In replication analyses in RADIANT-UK, not including IDS 
assessments, we focused on the available data of the number of endorsed DSM symptoms. 
RADIANT-UK showed the same pattern of a stronger association, as compared to overall MDD, 
     
 
between cases with high number of DSM symptoms and genetic risk score for schizophrenia.  
Our results showed that selection of cases with an early age at onset might represent another 
option to stratify MDD patients. This is underlined by the findings of a study based on the larger 
PGC-MDD data pool which found that GPRS-BIP is associated with an earlier age at MDD 
onset.(47)   
 Our results suggest that focusing on phenotypically more homogenous MDD subgroups 
of patients as stratified according to characteristics reflecting a more severe MDD phenotype, 
might be a solution to find SNPs/genes associated with MDD. This was recently supported by a 
GWAS that found two genetic-loci significantly contributing to the risk of MDD in a homogenous 
subgroup of Chinese women with recurrent MDD.(6) Besides standard clinical characteristics 
(recurrence, age at onset) to create phenotypically more homogenous MDD subgroups that are 
genetically more identical, there is evidence that subgroups based on symptom subtype 
(melancholic versus atypical MDD)(21) or postpartum depression(48) might  also be a possibility 
to identify genetic more homogenous MDD groups. Moreover, it could be useful to focus on 
subgroups exposed to a certain environmental factor when studying the genetic effect on 
MDD.(29)  
  The core strengths of our study are the large number of participants with available 
genetic data, well-characterized in terms of clinical MDD characteristics, representing different 
developmental stages of MDD. Moreover, we used GPRS based on large international consortia 
and we additionally built GPRS with the new LDpred approach, which is suggested to increase 
predictive accuracy above commonly used methods for GPRS.(32)  
  In conclusion, the present study showed that the genetic risk for three major psychiatric 
disorders is increased in persons with phenotypically more homogenous MDD according to 
characteristics reflecting a more severe MDD phenotype. Our results showed that MDD patients 
     
 
with an early age at onset, high number of DSM symptoms, and moderate to severe symptoms 
across years have the highest genetic risk. Our results suggest that in genetic studies for 
depression, in conjunction with a continuous effort in increasing sample sizes, it may be useful 
to create more homogenous subgroups based on those phenotypical characteristics in search 
for genes associated with MDD.   
ACKNOWLEDGEMENTS. 
NESDA 
The Netherlands Study of Depression and Anxiety and the Netherlands Twin Register: funding 
was obtained from the Netherlands Organization for Scientific Research (NWO) and 
MagW/ZonMW grants Middelgroot-911- 09-032, Spinozapremie 56-464-14192, Center for 
Medical Systems Biology (CSMB, NWO Genomics), Genetic influences on stability and change in 
psychopathology from childhood to young adulthood (ZonMW 912-10-020), NBIC/BioAssist/RK 
(2008.024), Biobanking and Biomolecular Resources Research Infrastructure (BBMRI–NL, 
184.021.007), VU University’s Institute for Health and Care Research (EMGO+) and Neuroscience 
Campus Amsterdam (NCA); the European Science Council (ERC Advanced, 230374).  
  The infrastructure for the NESDA study (www.nesda.nl) is funded through the 
Geestkracht program of the Netherlands Organization for Health Research and Development 
(ZonMw, grant number 10-000-1002) and is supported by participating universities and mental 
health care organizations (VU University Medical Centre, GGZ inGeest, Arkin, Leiden University 
Medical Centre, GGZ Rivierduinen, University Medical Centre Groningen, Lentis, GGZ Friesland, 
GGZ Drenthe, Institute for Quality of Health Care (IQ Healthcare), Netherlands Institute for 
Health Services Research (NIVEL) and Netherlands Institute of Mental Health and Addiction 
(Trimbos)). 
     
 
  Part of the genotyping and analyses were funded by the Genetic Association 
Information Network (GAIN) of the Foundation for the National Institutes of Health, Rutgers 
University Cell and DNA Repository (NIMH U24 MH068457-06), the Avera Institute, Sioux Falls, 
South Dakota (USA) and the National Institutes of Health (NIH R01 HD042157-01A1, MH081802, 
Grand Opportunity grants 1RC2 MH089951 and 1RC2 MH089995). Computing was supported by 
BiG Grid, the Dutch e- Science Grid, which is financially supported by NWO. We are grateful to 
the Psychiatric Genomics Consortium (MDD group) for providing the summary statistics for 
meta-analyses of MDD, BIP and SCZ after removal of the Dutch GWAS cohort. 
 
RADIANT-UK 
Genotyping of the UK RADIANT study was supported by the U.K. Medical Research Council 
(G0701420).  This paper represents independent research part-funded by the National Institute 
for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS 
Foundation Trust and King's College London.  
 
FINANCIAL DISCLOSURES 
All other authors report no biomedical financial interests or potential conflicts of interest.  
Supplemental material is available at the journal website.  
 
 
 
 
     
 
REFERENCES 
1. Sullivan PF, Neale MC, Kendler KS (2000): Genetic Epidemiology of Major Depression : Review 
and Meta-Analysis. Am J Psychiatry. 157: 1552–1562. 
2. Major Depressive Disorder working groups of the Psychiatric GWAS Consortium, Ripke S, 
Wray NR, Lewis CM, Hamilton SP, Weissman MM, et al. (2013): A mega-analysis of 
genome-wide association studies for major depressive disorder. Mol Psychiatry. 18: 497–
511. 
3. Levinson DF, Mostafavi S, Milaneschi Y, Rivera M, Ripke S, Wray NR, Sullivan PF (2014): 
Genetic studies of major depressive disorder: why are there no genome-wide association 
study findings and what can we do about it? Biol Psychiatry. 76: 510–2. 
4. Flint J, Kendler KS (2014): The genetics of major depression. Neuron. 81: 484–503. 
5. Lorenzo-Luaces L (2015): Heterogeneity in the prognosis of major depression: from the 
common cold to a highly debilitating and recurrent illness. Epidemiol Psychiatr Sci. 1–7. 
6. Cai N, Bigdeli TB, Kretzschmar W, Li Y, Liang J, Song L, et al. (2015): Sparse whole-genome 
sequencing identifies two loci for major depressive disorder. Nature. 000. doi: 
10.1038/nature14659. 
7. Hirschfeld RM a, Weissman MM (2002): Depression and Bipolar Disorder. 
Neuropsychopharmacol Fifth Gener Prog - Chapter 70 Risk factors Majord Depress Bipolar 
Disord. pp 1017–1025. 
8. Kendler KS, Gatz M, Gardner CO, Pedersen NL (2007): Clinical indices of familial depression in 
the Swedish Twin Registry. Acta Psychiatr Scand. 115: 214–20. 
9. Wray NR, Pergadia ML, Blackwood DHR, Penninx BWJH, Gordon SD, Nyholt DR, et al. (2012): 
Genome-wide association study of major depressive disorder: new results, meta-analysis, 
and lessons learned. Mol Psychiatry. 17: 36–48. 
10. Ferentinos P, Koukounari A, Power R, Rivera M, Uher R, Craddock N, et al. (2015): Familiality 
and SNP heritability of age at onset and episodicity in major depressive disorder. Psychol 
Med. 1–11. 
11. Fava GA, Kellner R (1993): Staging: a neglected dimension in psychiatric classification. Acta 
Psychiatr Scand. . 
12. Mcgorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ (2006): Clinical staging of psychiatric 
disorders: a heuristic framework for choosing earlier, safer and more effective 
interventions. Aust N Z J Psychiatry. 616–622. 
     
 
13. Hetrick SE, Parker a G, Hickie IB, Purcell R, Yung a R, McGorry PD (2008): Early identification 
and intervention in depressive disorders: towards a clinical staging model. Psychother 
Psychosom. 77: 263–70. 
14. Levine M, Crimmins E, Prescott C, Phillips D, Arpawong TE, Lee J (2014): A Polygenic Risk 
Score Associated with Measures of Depressive Symptoms Among Older Adults. 
Biodemography Soc Biol. 60: 199–211. 
15. Sklar P, Ripke S, Scott LJ, Andreassen O a, Cichon S, Craddock N, et al. (2011): Large-scale 
genome-wide association analysis of bipolar disorder identifies a new susceptibility locus 
near ODZ4. Nat Genet. 43: 977–983. 
16. Schizophrenia Working Group of the Psychiatric Genomics (2014): Biological insights from 
108 schizophrenia-associated genetic loci. Nature. 511: 421–7. 
17. Lewis CM, Ng MY, Butler AW, Cohen-Woods S, Uher R, Pirlo K, et al. (2010): Genome-wide 
association study of major recurrent depression in the U.K. population. Am J Psychiatry. 
167: 949–957. 
18. Boomsma DI, Willemsen G, Sullivan PF, Heutink P, Meijer P, Sondervan D, et al. (2008): 
Genome-wide association of major depression: description of samples for the GAIN Major 
Depressive Disorder Study: NTR and NESDA biobank projects. Eur J Hum Genet. 16: 335–
342. 
19. Penninx BWJH, Beekman ATF, Smit JH, Zitman FG, Nolen W a, Spinhoven P, et al. (2008): The 
Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. 
Int J Methods Psychiatr Res. 17: 121–40. 
20. Boomsma DI, de Geus EJC, Vink JM, Stubbe JH, Distel MA, Hottenga JJ, et al. (2006): 
Netherlands Twin Register: From Twins to Twin Families. Twin Res Hum Genet. 9: 849–857. 
21. Milaneschi Y, Lamers F, Peyrot WJ, Abdellaoui A, Willemsen G, Hottenga J, et al. (2016): 
Polygenic dissection of major depression clinical heterogeneity. Mol Psychiatry. 21: 516–
22. 
22. Wittchen H-U (1994): Reliability and Validity studies of the WHO-Composite International 
Diagnostic (CIDI): A critical review. J Psychiatr Res. 28: 57–84. 
23. Boomsma DI, Vink JM, van Beijsterveldt TCEM, de Geus EJC, Beem AL, Mulder EJCM, et al. 
(2002): Netherlands Twin Register: a focus on longitudinal research. Twin Res. 5: 401–6. 
24. Willemsen G, Vink JM, Abdellaoui A, den Braber A, van Beek JHDA, Draisma HHM, et al. 
(2013): The Adult Netherlands Twin Register: Twenty-Five Years of Survey and Biological 
Data Collection. Twin Res Hum Genet. 16: 271–281. 
     
 
25. Lyketsos CG, Nestadt G, Cwi J, Heithoff K, Eaton WW (1994): The life chart interview: a 
standardized method to describe the course of psychopathology. Int J Methods Psychiatr 
Res. . 
26. Fyer AJ, Weissman MM (1999): Genetic Linkage Study of Panic: Clinical Methodology and 
Description of Pedigrees. Am J Med Genet (Neuropsychiatric Genet. 88: 173–181. 
27. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH (1996): The Inventory of Depressive 
Symptomatology (IDS): psychometric properties. Psychol Med. 26: 477–86. 
28. Hickie IB, Scott EM, Hermens DF, Naismith SL, Guastella AJ, Kaur M, et al. (2013): Applying 
clinical staging to young people who present for mental health care. Early Interv Psychiatry. 
7: 31–43. 
29. Peyrot WJ, Milaneschi Y, Abdellaoui A, Sullivan PF, Hottenga JJ, Boomsma DI, Penninx BWJH 
(2014): Effect of polygenic risk scores on depression in childhood trauma. Br J Psychiatry. 
205: 113–9. 
30. Abdellaoui A, Hottenga J-J, de Knijff P, Nivard MG, Xiao X, Scheet P, et al. (2013): Population 
structure, migration, and diversifying selection in the Netherlands. Eur J Hum Genet. 21: 
1277–85. 
31. Yang J, Lee SH, Goddard ME, Visscher PM (2011): GCTA: A tool for genome-wide complex 
trait analysis. Am J Hum Genet. 88: 76–82. 
32. Vilhjálmsson BJ, Yang J, Finucane H (2015): Modeling Linkage Disequilibrium Increases 
Accuracy of Polygenic Risk Scores. bioRxiv. . 
33. Lee SH, Goddard ME, Wray NR, Visscher PM (2012): A better coefficient of determination for 
genetic profile analysis. Genet Epidemiol. 36: 214–24. 
34. De Graaf R, ten Have M, van Gool C, van Dorsselaer S (2012): Prevalence of mental disorders 
and trends from 1996 to 2009. Results from the Netherlands Mental Health Survey and 
Incidence Study-2. Soc Psychiatry Psychiatr Epidemiol. 47: 203–13. 
35. Wray NR, Lee SH, Mehta D, Vinkhuyzen A a E, Dudbridge F, Middeldorp CM (2014): Research 
Review: Polygenic methods and their application to psychiatric traits. J Child Psychol 
Psychiatry Allied Discip. 10: 1068–1087. 
36. Palla L, Dudbridge F (2015): A Fast Method that Uses Polygenic Scores to Estimate the 
Variance Explained by Genome-wide Marker Panels and the Proportion of Variants 
Affecting a Trait. Am J Hum Genet. 97: 250–259. 
37. MDD-PGC, Ripke S, Wray NR (2013): Supplemental Material : MDD GWAS Mega-Analysis 
Table of Contents. Mol Psychiatry. 18: S1–S77. 
38. Wing JK (1990): SCAN. Arch Gen Psychiatry. 47: 589. 
     
 
39. Peyrot WJ, Lee SH, Milaneschi Y, Abdellaoui A, Byrne EM, Esko T, et al. (2015): The 
association between lower educational attainment and depression owing to shared genetic 
effects? Results in ~25,000 subjects. Mol Psychiatry. 20: 735–43. 
40. Dudbridge F (2013): Power and predictive accuracy of polygenic risk scores. PLoS Genet. 9: 
e1003348. 
41. Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Keller M, et al. (1995): Switching from 
“unipolar” to bipolar II. An 11-year prospective study of clinical and temperamental 
predictors in 559 patients. Arch Gen Psychiatry. 52: 114–23. 
42. Benazzi F, Akiskal HS (2008): How best to identify a bipolar-related subtype among major 
depressive patients without spontaneous hypomania: superiority of age at onset criterion 
over recurrence and polarity? J Affect Disord. 107: 77–88. 
43. Woo YS, Shim IH, Wang H-R, Song HR, Jun T-Y, Bahk W-M (2015): A diagnosis of bipolar 
spectrum disorder predicts diagnostic conversion from unipolar depression to bipolar 
disorder: a 5-year retrospective study. J Affect Disord. 174: 83–8. 
44. Wiste A, Robinson EB, Milaneschi Y, Meier S, Ripke S, Clements CC, et al. (2014): Bipolar 
polygenic loading and bipolar spectrum features in major depressive disorder. Bipolar 
Disord. 608–616. 
45. Park S, Hahn S, Hwang T, Kim J, Jun T, Lee M, et al. (2014): Does Age at Onset of First Major 
Depressive Episode Indicate the Subtype of Major Depressive Disorder?: The Clinical 
Research Center for Depression Study. Yonsei Med J. 55: 1712–1720. 
46. American Psychiatric Association (APA) (2013): Diagnostic and Statistical Manual of Mental 
Disorders Fifth Edition, 5th ed. Arlington: American Psychiatric Association Pusblishing. 
47. The Psychiatric Genomics Consortium Major Depressive Disorder Working Group, Power RA, 
Tansey KE (n.d.): Genome-wide association study identifies variants for major depression 
through age at onset stratification. under Rev. . 
48. Byrne EM, Carrillo-Roa T, Penninx BWJH, Sallis HM, Viktorin A, Chapman B, et al. (2014): 
Applying polygenic risk scores to postpartum depression. Arch Womens Ment Health. 519–
528. 
 
     
 
TABLE & FIGURES LEGENDS 
Table 1. Descriptives of controls and MDD cases (n=3331), characteristics of MDD cases 
(n=1539). 
 
Figure 1: NESDA, % explained variance for MDD status (All MDD cases or those with DSM-
high/ISD-high/AaO-young) versus controls 
Explained variance assuming a liability threshold model and K=0.18 (MDD), K=0.18/4 (DSM, IDS 
and AaO quartiles), K=0.18/2 (DSM-high, IDS-high, AaO-young)  
P-values from binary (MDDall, DSM-high, IDS-high, AaO-young) and multinomial (subgroups) 
logistic regression (reference=controls, n=1792); adjusted for year of birth, gender and 3 
principal components 
 
Figure 2: RADIANT-UK, % explained variance for MDD status (All MDD cases or those with 
DSM-high) versus controls 
Explained variance assuming a liability threshold model and K=0.18 (MDD), K=0.18/2 (DSM-high) 
P-values from binary (MDDall, DSM-high) logistic regression (reference=controls, n=1390); 
adjusted for age, gender and 10 principal components 
 
Figure 3: NESDA, RADIANT-UK, POOLED, comparing odds ratios of MDD all cases versus DSM-
high cases, reference are controls.  
A: NESDA MDD CASES (n=1539) vs. MDD CASES DSM symptoms high (n=941), reference controls 
(n=1792) 
B: RADIANT-UK MDD CASES (n=1602) vs. MDD CASES DSM symptoms high (n=878), reference controls 
(n=1390) 
C: POOLED NESDA and RADIANT-UK, MDD CASES (n=3141) vs. MDD CASES DSM symptoms high 
(n=1819), controls (n=3182) 
  
     
 
Table 1. Descriptives of controls and MDD cases (n=3331), characteristics of MDD cases (n=1539). 
 
 
No MDD 
n=1792 
MDD 
n=1539 
Demographics   
Year of Birth, Med (IQR)a 1972 (1958–1979) 1962 (1952–1973) 
Gender (female), % (n)a 61.0 (1094) 68.0 (1047) 
Characteristics    
Age at Onset (yr), Med (IQR)  26.0 (18.0-38.0) 
Duration mean over 10 yrs (%), Med (IQR)  21.0 (6.62-46.5) 
Family History (yes), % (n)   75.7 (1165) 
Number of DSM symptoms highest ever, Med (IQR)  8.00 (7.00-9.00) 
Severity of Symptom (IDS) average score, M (SD)  21.7 (11.6) 
Recurring MDD, % (n) First (no)  29.4 (452) 
 Recurrent (yes)  70.0 (1078) 
Stage of MDD, % (n) Stage 2 (1st episode)  19.7 (303) 
 Stage 3 (recurrent episode)  41.0 (631) 
 Stage 4 (chronic)  39.3 (605) 
IDS=Inventory of Depressive Symptoms; IQR=Inter Quartile Range; M=Mean; MDD=Major Depressive Disorder; Med=Median; 
n=number; yr=year; SD=Standard Deviation. 
a p-value < .001 
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